Expansion into the central nervous system field through the acquisition of Abania
First written in FY2016. 2 of 5 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2017.
No other company in this theme has enough history to compare yet.
- FY2017AdvancedAnnual report
「Neurovance, Inc. was absorbed through a merger by Otsuka America Pharmaceutical, Inc., a consolidated subsidiary of the company, effective 30 November 2017.」
Following the acquisition of Neurovance in March 2017, it was absorbed through a merger by Otsuka America Pharmaceutical on 30 November of the same year. The integration of the central nervous system portfolio has advanced to the organisational integration stage. - FY2017-Q3RestatedAnnual report
「The company acquired Neurovance, Inc. in March 2017, and the development products acquired are currently at the following stages of development.」
The company reconfirmed the March 2017 acquisition of Neurovance and that the acquired ADHD treatment centanafadine is at the Phase II trial stage. - FY2017-Q2RestatedAnnual report
「The company acquired Neurovance, Inc. in March 2017, and the development products acquired are currently at the following stages of development.」
The company reconfirmed the March 2017 acquisition of Neurovance and that the acquired ADHD treatment centanafadine is undergoing a Phase II trial. Completion of the acquisition had already been disclosed in the previous quarter. - FY2017-Q1AdvancedAnnual report
「The company aims to further strengthen this area by acquiring a new central nervous system portfolio from Neurovance, Inc.」
On 17 March 2017, the company made Neurovance, Inc. a wholly owned subsidiary and acquired a new central nervous system portfolio, including the ADHD treatment centanafadine. - FY2016First statedAnnual report
「The company will accelerate its strategy to expand across the central nervous system field by integrating the business platform in psychiatric disorders, which it has developed over many years, with the business platform in neurological disorders strengthened through the acquisition of Avanir Pharmaceuticals, Inc.」
The integration of the psychiatric and neurological disease platforms through the acquisition of Avanir was identified separately for the first time as a specific means of expanding the central nervous system business.